^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) + Imlygic (talimogene laherparepvec) (GM-CSF agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
Excerpt:
...- Localized, palpable, biopsy proven triple negative or ER positive HER2 negative infiltrating ductal breast cancer with size > 1.5 cm by palpation, excluding breast cancer where neoadjuvant chemotherapy is indicated by current guidelines (i.e. inflammatory subtype, etc.)...
Trial ID:
Source:
Title:
A pilot study of neoadjuvant nivolumab, ipilimumab and intralesional oncolytic virotherapy for HER2-negative breast cancer
Published date:
07/27/2023
Excerpt:
Eligibility for this pilot phase 1 trial included patients with localized HER2-negative breast cancer who received systemic nivolumab and ipilimumab and intratumor talimogene laherparepvec…One patient had a pathological complete response, three patients had pathological partial responses, one showed no significant response, and one had disease progression. Biopsies demonstrated increased immune cell infiltration in samples from patients who responded to therapy....This triple immunotherapy regimen provided responses in patients with advanced or relapsed HER2-negative breast cancer, at the expense of long-term toxicities.
DOI:
https://doi.org/10.1158/2767-9764.CRC-23-0145
Trial ID:
